Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 oct. 2020 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 32nd EORTC-NCI-AACR Symposium on Molecular...
03 sept. 2020 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor...
02 sept. 2020 12h48 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated...
11 août 2020 16h05 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020. Loss from...
04 août 2020 07h00 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30...
29 juil. 2020 09h05 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Pricing of $12 Million Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its...
28 juil. 2020 16h07 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it intends to offer and sell, subject to market and other conditions,...
07 juil. 2020 16h01 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a reduction in workforce of approximately 30% of its head count to focus...
23 juin 2020 07h30 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program

SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor...
07 mai 2020 16h05 HE | Source: Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2020. Loss from...

Page précédente

Page suivante